Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

On Today with Claire Byrne, Maura Fay reports on the rollout of Mounjaro in Ireland and speaks to medical experts about issues surrounding access to this medication. Listen back above. The most ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

Across the SURPASS trial program, participants treated with Mounjaro had an average weight loss of between 12 and 25 pounds, depending on the strength of Mounjaro and co-administered medications.

With social media's history of hyped-up health trends, does a 'Mounjaro drink' drink deliver results - or is it just another internet myth? From 'sleepy girl cocktails' to 'oatzempic' drinks there ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

although the comparison was made before Novo Nordisk launched a higher-strength version of its drug. The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own ...

The volume increase was driven by growth from Mounjaro and Zepbound. Lower realized prices were primarily driven by Mounjaro, partially offset by Zepbound and Humalog. New Products revenue grew by ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...